Tag: chinese vaccine

  • NCOC approves Chinese vaccine for children aged 12 and older

    The National Command and Operation Centre (NCOC) announced on Thursday that its committee of health experts has approved two Chinese vaccines to be administered to children aged 12 years and older from November 15.

    The Chinese vaccines approved by the committee are Sinopharm and Sinovac.

    “Chinese vaccines Sinopharm and Sinovac have been approved by NCOC Health Expert Committee for administration to children above 12 years of age from 15 November onwards,” NCOC tweeted.

    “Now, these vaccines will also be available in addition to already approved Pfizer for children above 12 yrs,” tweeted NCOC.

    Earlier, Planning and Development Minister Asad Umar, who also heads NCOC, said more than 50 per cent of students between the ages of 12 and 18 have received at least one dose of coronavirus vaccine across the country.

  • Who will get the Pfizer vaccine in Pakistan?

    Who will get the Pfizer vaccine in Pakistan?

    Federal Minister for Planning and Development Asad Umar said on Thursday that the government has decided to prioritise giving the Pfizer vaccine to those who have a work visa. The government aims is to inoculate Hajj pilgrims and students proceeding for education abroad first.

    The federal minister said that the government is working hard to accelerate the vaccination process across the country so that restrictions are lifted and businesses are resumed.

    Umar, replying to a question, said that Pakistan had received a limited quantity of Pfizer this month and therefore, preference for its administration had to be given to some segments.

    However, he added, Pakistan would receive more doses of Pfizer in the future.

    The minister further warned that countries not accepting vaccination certificates of Chinese vaccines would turn out to be a problem for the entire world if a decision was not taken on the issue at the global level.

  • China’s current COVID-19 vaccines can tackle Indian variants, says expert

    China’s current COVID-19 vaccines can tackle Indian variants, says expert

    China’s current COVID-19 vaccines can fight new coronavirus variants spreading in India and can provide protection “to a certain extent”, based on preliminary research results, a disease control expert claimed on Thursday.

    Speaking at a news briefing, Shao Yiming, a researcher at the Chinese Centre for Disease Control and Prevention, did not elaborate on the specific vaccines or variants he referred to.

    Read more – Arjun Kapoor praises Pakistanis for offering help to India

    The World Health Organisation (WHO) said the predominant lineage of B.1.617 was first identified in India last December, although an earlier version was spotted in October 2020.

    The B.1.617 variant found contains two key mutations to the outer “spike” portion of the virus that attaches to human cells, said senior Indian virologist Shahid Jameel.

    The WHO has described it as a “variant of interest”, suggesting it may have mutations that would make the virus more transmissible, cause more severe disease or evade vaccine immunity. Other strains with known risks, such as those first detected in the United Kingdom, Brazil and South Africa, have been categorized as “variants of concern,” a higher threat level.

  • ‘79.3 per cent effective’: Govt to order 1.2m doses of Chinese vaccine

    ‘79.3 per cent effective’: Govt to order 1.2m doses of Chinese vaccine

    Pakistan has decided to purchase 1.2million doses of a Chinese vaccine, developed by China’s state-owned company Sinopharm, amid a worsening coronavirus outbreak across the world.

    According to Science and Technology Minister Fawad Chaudhry, the vaccine will be available in the first quarter of 2021 and it will be administered to frontline health workers in the first phase.

    “The Cabinet Committee has decided to initially purchase 1.2 million doses of the vaccine from the Chinese company Sinopharm, which will be provided free of cost to frontline workers in the first quarter of 2021,” the federal minister wrote on Twitter.

    Meanwhile, China has approved its first homegrown coronavirus vaccine, developed by state-owned pharmaceutical giant Sinopharm.

    CNN reported that the vaccine is 79.34% effective as per the interim analysis of Phase 3 clinical trials. China has drastically scaled up its vaccine emergency use program in recent weeks.

    Since December 15, the Chinese government has administered more than 3 million vaccine doses on “key groups” in the population, Zeng Yixin, vice-minister of China’s National Health Commission, said at a news conference.

    According to the report, fewer than 0.1 per cent developed a light fever, and about two people per million developed “relative serious adverse reactions” such as allergies.

    Beijing Biological Products Institute Co., a Sinopharm subsidiary, has said that interim results show the Sinopharm vaccine is safe and people who received two doses produced high-level antibodies.